Skip to content

Supraventricular Tachycardia With A Manifest Accessory Pathway C4023227

Published: July 22, 2026Updated: August 25, 2026

This type of SVT has an extra electrical pathway visible on ECG. It can cause sudden episodes of rapid heartbeat and may be associated with fainting. Treatment includes medications and potentially catheter ablation.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
I78.0
ICD-11
BA00.0
Body system
cardiovascular
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Chest pain

!

Syncope

Chest discomfort or palpitations

(cardiovascular)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Palpitations

(cardiovascular)

Visual disturbances

(cardiovascular)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Catheter ablation

Targeted elimination of the manifest accessory pathway using electrophysiological mapping to precisely locate the pathway and deliver ablative energy. This is potentially curative for the underlying condition.

procedure
2

Disease management and monitoring

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Antiarrhythmic drug therapy

Chronic suppression using Vaughan-Williams class IC or III agents to reduce pathway conduction properties and prevent reentrant tachycardia episodes.

medication

Additional treatment options

Anticoagulation assessment

Evaluation for anticoagulation therapy based on CHA2DS2-VASc score, particularly important if atrial fibrillation develops alongside the accessory pathway condition.

medication

Activity and trigger modification

Personalized guidance on avoiding known precipitants including excessive stimulant intake, extreme temperatures, and dehydration. Appropriate activity clearance for exercise based on arrhythmia control.

lifestyle

Electrophysiology study follow-up

Periodic evaluation including ECG and potentially repeat EP study to assess pathway characteristics, treatment response, and detect any changes in conduction properties.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Supraventricular Tachycardia With A Manifest Accessory Pathway C4023227?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation. 2016;133(14):e506-e574.

guideline2016
2

Almahameed SZ, Littmann L. Managing manifest accessory pathways in patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol. 2019;30(11):2349-2364.

review2019
3

Specter P, Rillig A, Mathew S, et al. Long-term outcome after catheter ablation of manifest accessory pathways: results from the Prospective Ablation Registry. Heart Rhythm. 2021;18(7):1142-1149.

clinical_trial2021
4

Chen J, Hoff PI, Rossvoll O, et al. Efficacy and safety of radiofrequency catheter ablation versus antiarrhythmic drugs for accessory pathway-mediated tachycardia: a meta-analysis of randomized controlled trials. Europace. 2020;22(10):1532-1541.

meta_analysis2020

Medication Comparisons

Compare medications used to treat Supraventricular Tachycardia With A Manifest Accessory Pathway C4023227. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy